Table 2. Parkinson’s disease (PD) and non-PD ‘control’ peers vascular risk variables.
| Measure | PD (n = 40) | Non-PD (n = 40) | t, u, x2 | p-value |
|---|---|---|---|---|
| Homocysteine | 12.23±4.40, 2.7/22.2 | 10.65±1.69, 7.4/14.7 | 2.76 | 0.03 |
| C Reactive Protein | 1.42±1.47, 0.20/17.60 | 2.02±2.79, 0.20/8.1 | -1.62 | 0.11 |
| Uric Acid | 5.31±1.06, 2.0/8.2 | 5.78±1.10, 2.9/7.6 | -1.91 | 0.06 |
| BP Systolic | 128.16±10.46, 107/149 | 136.63±11.26, 112/157 | -3.49 | 0.001 |
| BP Diastolic | 76.29±7.17, 62/93 | 78.30±6.40, 66/97.50 | -1.32 | 0.19 |
| Pulse Pressure | 51.87±7.55, 37.50/64.67 | 58.33±9.26, 40/75.33 | -3.42 | 0.001 |
| Leukoaraiosis raw mm3 | 4950±6748, 497/29694 | 4032.15±4477.81, 0/19978 | 0.72 | 0.48 |
| Leukoaraiosis/TICV % | 0.29±0.40, 0/2 | 0.25±0.28, 0/1 | 0.57 | 0.57 |
Homocysteine—expected range 5–15 μmol/L, with 7 (17%) of PD participants having cut-offs above the recommended cut-point; C-reactive protein expected range = 0–3 mg/L; Uric Acid expected range 3–7 mg/dL. BP = blood pressure (average of measurements if multiple recordings acquired; results similar if based on the first BP recording; Systolic, p = 0.001; Diastolic, p = 0.14; Pulse Pressure, p = 0.001). Leukoaraiosis/TICV % = Percent of Leukoaraiosis as a proportion of total intracranial volume.